Title: MPN-MDS EU Focus Meeting 2023
Activity Date: September 15-16 2023
This activity is jointly provided by Medical Education Resources and MD Education.
This activity has been designed to meet the educational needs of health care professionals involved in the care of patients with Myeloproliferative neoplasms (MPN) and Myelodysplastic syndrome (myelodysplasia).
The meeting will provide participants with a unique opportunity for sharing knowledge, skills and experiences. In addition, this event will provide a platform for networking with many of the world’s leading experts, focusing on reviewing and assessing best practices and state-of-the-art treatments to address the generic changes aimed at identifying and preventing hematologic malignancies. The meeting program will include presentations, round-table discussions, debates with audience participation, oral abstract and a number of informal social gatherings.
- Evaluate the progress in the development of new therapies and best practices for the treatment of MPN.
- Examine prognostics and the treatment of essential thrombocytosis (ET).
- Discuss the treatment of PV.
- Deliberate on recent progress in the treatment of MF including novel therapies in development.
- Employ approaches to improve outcome of transplant for MPN.
- Translate new findings into clinical practice.
- Evaluate the MDS classification systems.
- Examine MDS risk stratification.
- Review clinical trials and novel targeted therapy.
- Deliberate on MDS/MPN overlap.
- Describe MRD assessment in MDS.
- Employ approaches to translate new findings into clinical practice.
Medical Education Resources designates this live activity for a maximum of XXX AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Relevant Financial Relationships
Medical Education Resources ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards off experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business of interest of an ineligible company.
There are no fees for Healthcare Providers for this activity.